PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
September 16, 2025ProcessesOpen Access

Targeting PRMT5: Current Inhibitors and Emerging Strategies for Therapeutic Intervention

View Full Paper
Ask AI
Bookmark
Share

Authors

ZSZhihang ShenCLChenglong Li

Discussion

Loading...

Member takes

Overview

This review summarizes inhibitors of prmt5 and their potential in treating epigenetic dysregulation in cancer.

Key Points

  • PRMT5 inhibitors have shown promise in targeting epigenetic dysregulation in various cancers.
  • Notably, PRMT5 is associated with poor clinical outcomes, especially in MTAP-deficient cancers.
  • Recent advancements in inhibitor development have led to clinical trials for PRMT5 in advanced cancers.
  • Future strategies must address challenges in effectively targeting PRMT5 for therapeutic intervention.

Cite This Study

Shen et al. (2025) studied this question.

synapsesocial.com/papers/68d454d131b076d99fa5a929https://doi.org/10.3390/pr13092878
View Full Paper
Ask AI
Bookmark
Share